士泽生物医药

NeuSera is a clinical-stage biotechnology company specializing in the development of next-generation cell therapies derived from induced pluripotent stem cells (iPSCs). The company focuses on treating severe neurological disorders, including Parkinson's disease, ischemic stroke, and amyotrophic lateral sclerosis (ALS), by replacing damaged neurons with functional, iPSC-derived neural cells. NeuSera has established a proprietary platform for the large-scale, clinical-grade production of high-purity subtype-specific neurons. Their lead program for Parkinson's disease has demonstrated significant efficacy in preclinical models and is advancing through regulatory milestones in China and internationally. The company aims to provide off-the-shelf, standardized regenerative medicine solutions for unmet needs in the central nervous system space.